The New Era of Interferon-Free Treatment of Chronic Hepatitis C

Viszeralmedizin: Gastrointestinal Medicine and Surgery

Volumn 31, Issue 4, 2015, Pages 290-296

  Solbach, Philipp ^a   Wedemeyer, Heiner ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Cirrhosis; DAA; Direct acting antivirals; Drug resistance; Hepatitis C

Indexed keywords

ANTIVIRUS AGENT; DACLATASVIR; DASABUVIR; INTERFERON; LEDIPASVIR PLUS SOFOSBUVIR; NONSTRUCTURAL PROTEIN 5A INHIBITOR; NUCLEOSIDE DERIVATIVE; OMBITASVIR; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; PARITAPREVIR; PROTEINASE; PROTEINASE INHIBITOR; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CHRONIC HEPATITIS C; DISEASE COURSE; DRUG APPROVAL; GENOTYPE; HUMAN; INCIDENCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; REVIEW; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS LOAD; VIRUS REPLICATION;

EID: 84941559915     PISSN: 16626664     EISSN: 16626672     Source Type: Journal    
DOI: 10.1159/000433594     Document Type: Review

References (44)

1. Lee MH, Yang HI, Lu SN, Jen CL, You SL, Wang LY, Wang CH, Chen WJ, Chen CJ; R. E. V. E. A. L.-HCV Study Group: Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: A community-based long-term prospective study. J Infect Dis 2012; 206: 469-477.
2. Maasoumy B, Wedemeyer H: Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol 2012; 26: 401-412.
3. Razavi H, Waked I, Sarrazin C, et al: The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat 2014; 21(suppl 1):34-59.
4. van der Meer AJ, Veldt BJ, Feld JJ, et al: Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584-2593.
5. Sarrazin C, Berg T, Ross RS, et al: Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: The German guidelines on the management of HCV infection (Article in German). Z Gastroenterol 2010; 48: 289-351.
6. Wedemeyer H, Duberg AS, Buti M, et al: Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat 2014; 21(suppl 1):60-89.
7. Heidrich B, Wiegand SB, Buggisch P, et al: Treatment of naive patients with chronic hepatitis C genotypes 2 and 3 with pegylated interferon alpha and ribavirin in a real world setting: relevance for the new era of DAA. PloS One 2014; 9:e108751.
8. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R: Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110-113.
9. Hinrichsen H, Benhamou Y, Wedemeyer H, et al: Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype-1 patients. Gastroenterology 2004; 127: 1347-1355.
10. Tomei L, Failla C, Santolini E, De Francesco R, La Monica N: NS3 is a serine protease required for processing of hepatitis C virus polyprotein. J Virol 1993; 67: 4017-4026.
11. Jacobson IM, McHutchison JG, Dusheiko G, et al: Telaprevir for previously untreated chronic hepatitis C virus infection. New Engl J Med 2011; 364: 2405-2416.
12. Poordad F, McCone J Jr, Bacon BR, et al: Boceprevir for untreated chronic HCV genotype 1 infection. New Engl J Med 2011; 364: 1195-1206.
13. www. accessdata. fda. gov/drugsatfda-docs/label/2012/ 201917s007lbl. pdf.
14. Sarrazin C, Berg T, Cornberg M, et al: Expert opinion on boceprevir-and telaprevir-based triple therapies of chronic hepatitis C (Article in German). Z Gastroenterol 2012; 50: 57-72.
15. Sherman KE, Flamm SL, Afdhal NH, et al: Responseguided telaprevir combination treatment for hepatitis C virus infection. New Engl J Med 2011; 365: 1014-1024.
16. Jacobson IM, Dore GJ, Foster GR, et al: Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): A phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014; 384: 403-413.
17. Manns M, Marcellin P, Poordad F, et al: Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2014; 384: 414-426.
18. Jensen DM O'Leary J, Pockros P, et al. ; for the HCVTARGET Study Group: Safety and Efficacy of Sofosbuvir-Containing Regimens for Hepatitis C: Real-World Experience in a Diverse, Longitudinal Observational Cohort. 65th Annual Meeting of the American Association for the Study of Liver Diseases. November 7-11, 2014, Boston, USA. Abstract 45. www. natap. org/2014/ AASLD/AASLD-10. htm.
19. Lok AS, Gardiner DF, Lawitz E, et al: Preliminary study of two antiviral agents for hepatitis C genotype 1. New Engl J Med 2012; 366: 216-224.
20. Gao M, Nettles RE, Belema M, et al: Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465: 96-100.
21. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al: Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. New Engl J Med 2014; 370: 211-221.
22. Manns M, Pol S, Jacobson IM, et al: All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: A multinational, phase 3, multicohort study. Lancet 2014; 384: 1597-1605.
23. Zeuzem S, Hezode C, Bronowicki J-P, et al: Daclatasvir in Combination with Simeprevir with or without Ribavirin for Hepatitis C Virus Genotype 1 Infection. 21st Conference on Retroviruses and Opportunistic Infections. March 3-6, 2014. Boston, USA. www. natap. org/2014/CROI/croi-09. htm.
24. Donaldson EF, Harrington PR, O'Rear JJ, Naeger LK: Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir. Hepatology 2015; 61: 56-65.
25. Jacobson IM, Gordon SC, Kowdley KV, et al: Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. New Engl J Med 2013; 368: 1867-1877.
26. Zeuzem S, Dusheiko GM, Salupere R, et al: Sofosbuvir + Ribavirin for 12 or 24 Weeks for Patients with HCV Genotype 2 or 3: The VALENCE trial. 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2013). November 1-5, 2013. Washington, DC, USA. www. natap. org/2013/AASLD/ AASLD-15. htm.
27. Lawitz E, Sulkowski MS, Ghalib R, et al: Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: The COSMOS randomised study. Lancet 2014; 384: 1756-1765.
28. Dieterich D, Bacon BR, Flamm S, et al. : Evaluation of Sofosbuvir and Simeprevir-Based Regimens in the TRIO Network: Academic and Community Treatment of a Real-World, Heterogeneous Population. 65th Annual Meeting of the American Association for the Study of Liver Diseases. November 7-11, 2014. Boston, USA. Abstract 46. www. natap. org/2014/AASLD/AASLD-09. htm.
29. Afdhal N, Zeuzem S, Kwo P, et al: Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. New Engl J Med 2014; 370: 1889-1898.
30. Afdhal N, Reddy KR, Nelson DR, et al: Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. New Engl J Med 2014; 370: 1483-1493.
31. Kowdley KV, Gordon SC, Reddy KR, et al: Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. New Engl J Med 2014; 370: 1879-1888.
32. Bourlière Sulkowski MS, Omata M, et al: Integrated Safety and Efficacy Analysis of >500 Patients with Compensated Cirrhosis Treated with Ledipasvir/ Sofosbuvir with or without Ribavirin. 65th Annual Meeting of the American Association for the Study of Liver Diseases. November 7-11, 2014. Boston, USA. Abstract 82.
33. Feld JJ, Kowdley KV, Coakley E, et al: Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. New Engl J Med 2014; 370: 1594-1603.
34. Ferenci P, Bernstein D, Lalezari J, et al: ABT-450/rombitasvir and dasabuvir with or without ribavirin for HCV. New Engl J Med 2014; 370: 1983-1992.
35. Poordad F, Hezode C, Trinh R, et al: ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. New Engl J Med 2014; 370: 1973-1982.
36. Zeuzem S, Jacobson IM, Baykal T, et al: Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. New Engl J Med 2014; 370: 1604-1614.
37. Lawitz E, Mangia A, Wyles D, et al: Sofosbuvir for previously untreated chronic hepatitis C infection. New Engl J Med 2013; 368: 1878-1887.
38. Zeuzem S, Dusheiko GM, Salupere R, et al: Sofosbuvir and ribavirin in HCV genotypes 2 and 3. New Engl J Med 2014; 370: 1993-2001.
39. Nelson DR, Cooper JN, Lalezari JP, et al: All-Oral 12-Week Combination Treatment with Daclatasvir and Sofosbuvir in Patients Infected with HCV Genotype 3: ALLY-3 Phase 3 Study. 65th Annual Meeting of the American Association for the Study of Liver Diseases. November 7-11, 2014. Boston, USA. Abstract LB-3. www. natap. org/2015/EASL/EASL-73. htm.
40. Gane EJ, Hyland HR, An D, et al: Sofosbuvir/Ledipasvir Fixed Dose Combination Is Safe and Effective in Difficult-to-Treat Populations Including Genotype-3 Patients, Decompensated Genotype-1 Patients, and Genotype-1 Patients with Prior Sofosbuvir Treatment Experience. Program and abstracts of the 49th Annual Meeting of the European Association for the Study of the Liver. April 9-13, 2014. London, England. Abstract 06. J Hepatol 2014; 60(suppl):S3-S4.
41. Kapoor R, Kohli A, Sidharthan S et al: Treatment of Hepatitis C Genotype 4 with Ledipasvir and Sofosbuvir for 12 Weeks: Results of the SYNERGY Trial. 65th Annual Meeting of the American Association for the Study of Liver Diseases. November 7-11, 2014. Boston, USA. Abstract 240.
42. Ruane PJ, Ain D, Meshrekey R, et al: Sofosbuvir plus Ribavirin, an Interferon-Free Regimen, in the Treatment of Treatment-Naive and Treatment-Experienced Patients with Chronic Genotype 4 HCV Infection. 49th Annual Meeting of the European Association for the Study of Liver Diseases. April 9-13, 2014. London, England. Abstract P1243.
43. Pol S, Reddy KR, Baykal T, et al: Interferon-Free Regimens of Ombitasvir and ABT-450/r with or without Ribavirin in Patients with HCV Genotype 4 Infection: PEARL-I Study Results. 65th Annual Meeting of the American Association for the Study of Liver Diseases. November 7-11, 2014. Boston, USA. Abstract 1928.
44. Cornberg M, Höner zu Siederdissen C, Maasoumy B, Solbach P, Manns MP, Wedemeyer H: Standard therapy of chronic hepatitis C virus infection; in Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H (eds): Hepatology. A Clinical Textbook, ed 6. Flying Publisher, 2015, pp 221-286.